# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
On September 4, 2025, Cyclacel Pharmaceuticals, Inc. (the "Company") entered into a Warrant Exchange Agreement (the ...
After sharing encouraging preclinical results for a potential biliary tract cancer treatment, Cyclacel Pharmaceuticals jumped 3...
Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis